|
JP2012176958A
|
|
Treatment of smooth muscle hyperactivity by (r)-oxybutynin and (r)-desethyloxybutynin
|
|
CA2823655A1
|
|
Methods for treating prostatitis
|
|
EP2782558A1
|
|
Immediate release abuse deterrent tablet
|
|
WO2012074830A2
|
|
Modified release tranexamic acid formulation
|
|
WO2008106536A1
|
|
Use of silodosin in a once daily administration for treating benign prostatic hyperplasia
|
|
US2009004284A1
|
|
Controlled release tamsulosin hydrochloride formulation
|
|
AU2007224129A1
|
|
Oral controlled release formulation for sedative and hypnotic agents
|
|
EP1912631A2
|
|
Diltiazem controlled release formulation and method of manufacture
|
|
AU2004222794A8
|
|
Non-oral androgenic steroids for women
|
|
US2005226898A1
|
|
Compositions and methods for transdermal oxybutynin therapy
|
|
US2005100608A1
|
|
Testosterone oral dosage formulations and associated methods
|
|
US7959946B2
|
|
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
|
US7785627B2
|
|
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
|
US2004202704A1
|
|
Transdermal delivery systems and methods
|
|
AU2003268361A8
|
|
Drug delivery system for treating urinary incontinence
|
|
AU2003235046A1
|
|
Pressure sensitive adhesive matrix patch for the treatment of onychomycosis
|
|
US2004037873A1
|
|
Norethindrone sustained release formulations and methods associated therewith
|
|
AU2003243143A1
|
|
2-methyl-thieno-benzodiazepine process
|
|
WO03078500A1
|
|
Polyalkylene graft polymers
|
|
US2003108606A1
|
|
Pharmaceutical formulation
|
